-
Zacks #5 Rank Additions for Friday - Tale of the Tape
Friday, November 12, 2010 - 9:30am | 346Here are 5 stocks added to the Zacks #5 Rank ("strong sell") List today: Alaska Comm Sys Group Inc (ALSK) Albany Molecular Research Inc (AMRI) AllianceBernstein Holding LP (AB) Amdocs Ltd (DOX) Ameron Intl Corp (AMN) View the entire Zacks #5 Rank List. ALLIANCEBERNSTN (AB): Free Stock Analysis...
-
Benzinga's Top Upgrades (GOV, QGEN, AH, GMET)
Friday, November 12, 2010 - 8:57am | 149Government Properties Income Trust (NYSE: GOV) was upgraded by Janney Montgomery Scott from "neutral" to "buy." GOV's shares closed at $26.36 yesterday. Shares of GOV have risen 19.98% year-to-date. Piper Jaffray upgrade Qiagen NV (NASDAQ: QGEN) from "neutral" to "overweight." QGEN's shares closed...
-
Piper Jaffray Upgrades QGEN To Overweight
Friday, November 12, 2010 - 7:50am | 48Analysts at Piper Jaffray upgrade Qiagen NV (NASDAQ: QGEN) from "neutral" to "overweight." The target price for QGEN is set to $21. QGEN's shares lost 0.49% to close at $18.36 yesterday. More Analyst Ratings here
-
Wider Loss at Amylin - Analyst Blog
Thursday, November 11, 2010 - 1:33pm | 983Amylin Pharmaceuticals (AMLN) reported a net loss of 31 cents per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the year-earlier loss of 19 cents. Lower revenues resulted in the wider loss. Revenues of $156.1 million missed the Zacks Consensus...
-
Narrower Loss at Medivation - Analyst Blog
Thursday, November 11, 2010 - 12:03pm | 522Medivation Inc. (MDVN) reported a loss of 16 cents per share in the third quarter of 2010, narrower than the Zacks Consensus Estimate of a loss of 21 cents and the year-ago loss of 42 cents. Lower expenses led to the narrower loss. Revenues for the quarter were $14.4 million, well below the Zacks...
-
VirtualScopics Reports 3rd Quarter Net Income of $0.98M
Thursday, November 11, 2010 - 9:35am | 116VirtualScopics, Inc. (Nasdaq: VSCP) today reported revenues of $3,590,591 for the third quarter of 2010 compared to revenues of $2,797,680 in the third quarter of 2009, a 28% increase. Excluding work performed in 2009 for the Department of Defense under projects that ended in 2009, the company...
-
Wuxi Pharmatech Inc.'s Strong Performance Increases Estimates
Thursday, November 11, 2010 - 9:32am | 119Oppenheimer published its quarterly update on WuXi Pharmatech Inc. (NYSE: WX) yesterday and they have increased estimates as well as the price target. Oppenheimer increased their 2011 revenue and EPS estimates by 2.3% and 7.8%. This comes after WX reported 3Q10 revenue of %83.8M which was 5.5%...
-
WX and HAL Rated Outperform
Thursday, November 11, 2010 - 9:02am | 105In Oppenheimer's Morning Research Summary both Halliburton Company (NYSE: HAL), and WuXi Pharmatech Inc. (NYSE: WX), have Outperform ratings. After attending HAL analyst meetings this week, Oppenheimer states that they "came away comfortable with our positive view of the stock (even for NAM...
-
ERT Files Shelf Registration Statement to Sell Securities for $150M
Wednesday, November 10, 2010 - 5:53pm | 107eResearchTechnology, Inc. (Nasdaq: ERES) today announced it has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission. Tthe registration statement, when declared effective by the SEC, will permit the Company to offer and sell from time to time in one or more...
-
Qiagen Beats but Cuts Rev Guidance - Analyst Blog
Wednesday, November 10, 2010 - 10:30am | 551Qiagen (QGEN) reported an EPS of 15 cents for the third quarter of fiscal 2010 compared to 18 cents in the year-ago period. However, after making some adjustments and treating stock-based compensation as a normal expense, the EPS came in at 24 cents, beating the Zacks Consensus Estimate by a...
-
WuXi PharmaTech 3Q10 Above Jefferies & Company Estimate
Wednesday, November 10, 2010 - 9:53am | 57WuXi PharmaTech (NYSE: WX) reported 3Q10 EPS of $0.27 after adjusting for intangible amortization and transaction-related items, Jefferies & Company reports. “Revenue was $83.8M,” Jefferies & Company writes. “Our estimate was $0.19 on $80.2M. The company issued 2010 revenue guidance of $...
-
Benzinga's Top Upgrades (AAP, GPRO, CUZ, TMO)
Wednesday, November 10, 2010 - 8:41am | 154Advance Auto Parts Inc (NYSE: AAP) was upgraded by Oppenheimer & Co from "underperform" to "perform." AAP's shares closed at $66.01 yesterday. Shares of Advance Auto Parts have moved up 63.63% year-to-date. Macquarie Capital Markets upgrade Gen-Probe Incorporated (NASDAQ: GPRO) from "...
-
Top 4 Stocks In The Medical Laboratories & Research Industry With The Highest Cash (ALR, PPDI, CVD, DGX)
Wednesday, November 10, 2010 - 4:52am | 130Below are the top medical laboratories & research stocks on the NYSE and the NASDAQ in terms of cash. Alere Inc (NYSE: ALR) had $493.27 million in total cash for the latest quarter and its total debt amounted to $2.39 billion. Pharmaceutical Product Development Inc (NASDAQ: PPDI) had $492.13...
-
Pharma & Biotech Industry Outlook - Nov. 2010 - Zacks Analyst Interviews
Tuesday, November 9, 2010 - 6:03pm | 2720With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new...
-
Pharma & Biotech Industry Outlook - Nov. 2010 - Industry Outlook
Tuesday, November 9, 2010 - 6:03pm | 2720With 2010 coming to an end, the pharmaceutical industry continues to witness major challenges like sluggish prescription trends, EU pricing pressure, intensifying generic competition and limited late-stage catalysts. The next five years are expected to reflect a significant imbalance between new...